Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Kumar R, Kala P, Narayanan GS, et al. Evaluation and evolution of apparent diffusion coefficient (ADC) in image-guided adaptive brachytherapy (IGABT) for cervical cancer. Brachytherapy. 2021;20(1):112–7.
Klopp AH. Introduction: Cervical cancer. Semin Radiat Oncol. 2020;30(4):263–4.
Lemp JM, De Neve JW, Bussmann H, et al. Lifetime prevalence of cervical cancer screening in 55 low- and middle-income countries. JAMA. 2020;324(15):1532–42.
Article PubMed PubMed Central Google Scholar
Abdel-Wahab M, Grover S, Zubizarreta EH, et al. Addressing the burden of cervical cancer through IAEA global brachytherapy initiatives. Brachytherapy. 2020;19(6):850–6.
Article PubMed PubMed Central Google Scholar
Malikova H, Burghardtova M, Fejfarova K, et al. Advanced cervical cancer in young women: imaging study of late and very late radiation-related side effects after successful treatment by combined radiotherapy. Quant Imaging Med Surg. 2021;11(1):21–31.
Article PubMed PubMed Central Google Scholar
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.
Article CAS PubMed PubMed Central Google Scholar
Hung T, Chang HY. Long noncoding RNA in genome regulation: prospects and mechanisms. RNA Biol. 2010;7(5):582–5.
Article CAS PubMed PubMed Central Google Scholar
Ko NY, Chen LR, Chen KH. The role of micro RNA and long-non-coding RNA in osteoporosis. Int J Mol Sci. 2020;21(14):4886.
Wang Y, Wang Y, Qin Z, et al. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol. 2021;17(3):291–306.
Article CAS PubMed Google Scholar
Qi X, Zhang DH, Wu N, et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52(10):710–8.
Conte F, Fiscon G, Sibilio P, et al. An overview of the computational models dealing with the regulatory ceRNA mechanism and ceRNA deregulation in cancer. Methods Mol Biol. 2021;2324:149–64.
Article CAS PubMed Google Scholar
Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
Article PubMed PubMed Central Google Scholar
Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21(1):22–36.
Article CAS PubMed Google Scholar
Bai X, Wang W, Zhao P, et al. LncRNA CRNDE acts as an oncogene in cervical cancer through sponging miR-183 to regulate CCNB1 expression. Carcinogenesis. 2020;41(1):111–21.
Ji YY, Meng M, Miao Y. lncRNA SNHG1 promotes progression of cervical cancer through miR-195/NEK2 axis. Cancer Manag Res. 2020;12:11423–33.
Article CAS PubMed PubMed Central Google Scholar
Cui X, Wang X, Zhou X, et al. miR-106a regulates cell proliferation and autophagy by targeting LKB1 in HPV-16-associated cervical cancer. Mol Cancer Res. 2020;18(8):1129–41.
Article CAS PubMed Google Scholar
Maass PG, Luft FC, Bahring S. Long non-coding RNA in health and disease. J Mol Med (Berl). 2014;92(4):337–46.
Article CAS PubMed Google Scholar
Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–6.
Article ADS CAS PubMed PubMed Central Google Scholar
Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.
Article CAS PubMed PubMed Central Google Scholar
Wang Q, Wu J, Huang H, et al. lncRNA LIFR-AS1 suppresses invasion and metastasis of non-small cell lung cancer via the miR-942-5p/ZNF471 axis. Cancer Cell Int. 2020;20:180.
Article PubMed PubMed Central Google Scholar
Xu F, Li H, Hu C. LIFR-AS1 modulates Sufu to inhibit cell proliferation and migration by miR-197-3p in breast cancer. Biosci Rep. 2019;39(7):BSR20180551.
Wang HF, Lv JQ, Li HH, et al. High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma. Eur Rev Med Pharmacol Sci. 2020;24(10):5378–84.
Muller H, Bracken AP, Vernell R, et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 2001;15(3):267–85.
Article CAS PubMed PubMed Central Google Scholar
Biswas AK, Johnson DG. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res. 2012;72(1):13–7.
Article CAS PubMed Google Scholar
Berton TR, Mitchell DL, Guo R, et al. Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation. Oncogene. 2005;24(15):2449–60.
Article CAS PubMed Google Scholar
Engelmann D, Putzer BM. The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 2012;72(3):571–5.
Article CAS PubMed Google Scholar
Smits VA, Medema RH. Checking out the G(2)/M transition. Biochim Biophys Acta. 2001;1519(1–2):1–12.
Suzuki T, Urano T, Miki Y, et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 2007;98(5):644–51.
Article CAS PubMed Google Scholar
Jin J, Xu H, Li W, et al. LINC00346 acts as a competing endogenous RNA regulating development of hepatocellular carcinoma via modulating CDK1/CCNB1 axis. Front Bioeng Biotechnol. 2020;8:54.
Article PubMed PubMed Central Google Scholar
Li S, Liu N, Piao J, et al. CCNB1 expedites the progression of cervical squamous cell carcinoma via the regulation by FOXM1. Onco Targets Ther. 2020;13:12383–95.
Article CAS PubMed PubMed Central Google Scholar
Zhang S, Iyer S, Ran H, et al. Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer. Cancer Discov. 2021;11(2):362–83.
Article CAS PubMed Google Scholar
Huang X, Shao D, Wu H, et al. Genomic profiling comparison of germline BRCA and non-BRCA carriers reveals CCNE1 amplification as a risk factor for non-BRCA carriers in patients with triple-negative breast cancer. Front Oncol. 2020;10:583314.
Article PubMed PubMed Central Google Scholar
Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137–54.
留言 (0)